Axsome Therapeutics, Inc. reported $777M of revenue over the trailing twelve months, +57% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $777M (to Q2 2026). Net income: −$192M, trailing twelve months to Q2 2026. Free cash flow: −$72M, trailing twelve months to Q2 2026. Operating margin: −24%, trailing twelve months to Q2 2026.

AXSMAxsome Therapeutics, Inc.

Healthcare

$168.44+45% 1Y

$168.44

$116.0152 weeks$255.17

AXSM as reported

Axsome Therapeutics, Inc. reported $777M of revenue over the trailing twelve months, +57% on the year before. 10 reported series are charted on this page, each one as filed.

$777M

Revenue, trailing twelve months · to Q2 2026 · +57% against the twelve months before

Net income: −$192M
Net income · −22% year on year · trailing twelve months to Q2 2026
Free cash flow: −$72M
Free cash flow · −41% year on year · trailing twelve months to Q2 2026
Operating margin: −24%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AXSM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$777M	+57%	Q2 2026
Net income	−$192M	−22%	Q2 2026
EPS	−$3.74	−26%	Q2 2026
Gross margin	93%	n/a	Q2 2026
Operating margin	−24%	n/a	Q2 2026
Net margin	−25%	n/a	Q2 2026
ROE	−273%	n/a	Q2 2026
ROA	−28%	n/a	Q2 2026
ROIC	266%	n/a	Q2 2026
Free cash flow	−$72M	−41%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.